de Mello Schier Alexandre R, de Oliveira Ribeiro Natalia P, Coutinho Danielle S, Machado Sergio, Arias-Carrión Oscar, Crippa Jose A, Zuardi Antonio W, Nardi Antonio E, Silva Adriana C
Institute of Psychiatry - Federal University of Rio de Janeiro. Laboratory of Panic and Respiration. Rua Visconde de Piraja, 407/702, Rio de Janeiro, RJ. CEP 22410-003, Brazil.
CNS Neurol Disord Drug Targets. 2014;13(6):953-60. doi: 10.2174/1871527313666140612114838.
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
焦虑和抑郁是影响人类生活诸多方面的病症，包括社交生活、生产力和健康。大麻二酚（CBD）是大麻的一种非致幻成分，具有巨大的精神治疗潜力，包括用作抗抑郁样和抗焦虑样化合物。本研究的目的是综述将CBD用作抗焦虑样和抗抑郁样化合物的动物模型研究。涉及动物模型的研究，针对上述病症进行了各种实验，如强迫游泳试验（FST）、高架十字迷宫试验（EPM）和 Vogel 冲突试验（VCT），表明CBD在所述动物模型中表现出抗焦虑和抗抑郁作用。CBD实验表明神经受体CB1和CB2未被激活。大多数研究表明CBD与5-HT1A神经受体之间有良好的相互作用。
